HomeCompareRPHM vs NNN

RPHM vs NNN: Dividend Comparison 2026

RPHM yields 10.99% · NNN yields 5.66%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 RPHM wins by $15.8K in total portfolio value
10 years
RPHM
RPHM
● Live price
10.99%
Share price
$18.20
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$41.3K
Annual income
$2,186.89
Full RPHM calculator →
NNN
NNN REIT Inc.
● Live price
5.66%
Share price
$42.03
Annual div
$2.38
5Y div CAGR
8.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$25.5K
Annual income
$2,622.67
Full NNN calculator →

Portfolio growth — RPHM vs NNN

📍 RPHM pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodRPHMNNN
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, RPHM + NNN cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
RPHM pays
NNN pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

RPHM
Annual income on $10K today (after 15% tax)
$934.07/yr
After 10yr DRIP, annual income (after tax)
$1,858.86/yr
NNN
Annual income on $10K today (after 15% tax)
$481.32/yr
After 10yr DRIP, annual income (after tax)
$2,229.27/yr
At 15% tax rate, NNN beats the other by $370.41/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of RPHM + NNN for your $10,000?

RPHM: 50%NNN: 50%
100% NNN50/50100% RPHM
Portfolio after 10yr
$33.4K
Annual income
$2,404.78/yr
Blended yield
7.20%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on NNN right now

RPHM
No analyst data
Altman Z
-0.1
Piotroski
3/9
NNN
Analyst Ratings
10
Buy
15
Hold
4
Sell
Consensus: Hold
Price Target
$44.93
+6.9% upside vs current
Range: $43.00 — $48.50
Altman Z
1.1
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

RPHM buys
0
NNN buys
2
PoliticianChamberTickerTypeAmountDate
Lisa McClain🏢 House$NNN▼ Sell$1,001 - $15,0002025-08-13
Lisa McClain🏢 House$NNN▲ Buy$1,001 - $15,0002025-06-17
Zoe Lofgren🏢 House$NNN▼ Sell$1,001 - $15,0002023-05-25
Ro Khanna🏢 House$NNN▼ Sell$1,001 - $15,0002022-01-20
Zoe Lofgren🏢 House$NNN▲ Buy$1,001 - $15,0002021-09-30
Zoe Lofgren🏢 House$NNN▼ Sell$1,001 - $15,0002020-03-23
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricRPHMNNN
Forward yield10.99%5.66%
Annual dividend / share$2.00$2.38
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%8.6%
Portfolio after 10y$41.3K$25.5K
Annual income after 10y$2,186.89$2,622.67
Total dividends collected$16.4K$13.7K
Payment frequencyquarterlyquarterly
SectorStockREIT

Year-by-year: RPHM vs NNN ($10,000, DRIP)

YearRPHM PortfolioRPHM Income/yrNNN PortfolioNNN Income/yrGap
1← crossover$11,799$1,098.90$10,735$614.96+$1.1KRPHM
2$13,837$1,211.76$11,572$708.43+$2.3KRPHM
3$16,133$1,328.07$12,531$819.53+$3.6KRPHM
4$18,710$1,447.20$13,633$952.29+$5.1KRPHM
5$21,588$1,568.52$14,909$1,111.84+$6.7KRPHM
6$24,791$1,691.42$16,392$1,304.77+$8.4KRPHM
7$28,341$1,815.27$18,129$1,539.52+$10.2KRPHM
8$32,264$1,939.50$20,173$1,827.08+$12.1KRPHM
9$36,587$2,063.54$22,597$2,181.81+$14.0KRPHM
10$41,334$2,186.89$25,491$2,622.67+$15.8KRPHM

RPHM vs NNN: Complete Analysis 2026

RPHMStock

Reneo Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the development of therapies for patients with rare genetic mitochondrial diseases. It develops REN001, a selective peroxisome proliferator-activated receptor delta agonist, which is in Phase IIb clinical trial in patients with primary mitochondrial myopathies, as well as in Phase 1b clinical trial in patients with long-chain fatty acid oxidation disorders and glycogen storage disease type V. Reneo Pharmaceuticals, Inc. was incorporated in 2014 and is headquartered in San Diego, California.

Full RPHM Calculator →

NNNREIT

National Retail Properties invests primarily in high-quality retail properties subject generally to long-term, net leases. As of September 30, 2020, the company owned 3,114 properties in 48 states with a gross leasable area of approximately 32.4 million square feet and with a weighted average remaining lease term of 10.7 years.

Full NNN Calculator →
📬

Get this RPHM vs NNN comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

RPHM vs SCHDRPHM vs JEPIRPHM vs ORPHM vs KORPHM vs MAINRPHM vs ADCRPHM vs EPRTRPHM vs FCPT

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.